Merck & Co., Inc. Announces FDA Acceptance of Resubmission of New Drug Application for Sugammadex Sodium Injection
Published: Jan 07, 2013
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the resubmission of the New Drug Application (NDA) for sugammadex sodium injection has been accepted for review by the U.S. Food and Drug Administration (FDA). Merck expects the FDA’s review to be completed in the first half of 2013.